Meningococcal vaccine groups A C Y W-135 conjugate - Aimei Vacin BioPharm
Alternative Names: A, C, Y, W135 meningococcal polysaccharide conjugate vaccine - Aimei Vacin BioPharmLatest Information Update: 19 Apr 2024
At a glance
- Originator Aimei Vacin BioPharm (Zhejiang)
 - Class Conjugate vaccines; Meningococcal vaccines
 - Mechanism of Action Immunostimulants
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- Preclinical Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
 
Most Recent Events
- 29 Mar 2024 Preclinical trials in Meningococcal group A infections (Prevention) in China (Parenteral)
 - 29 Mar 2024 Preclinical trials in Meningococcal group C infections (Prevention) in China (Parenteral)
 - 29 Mar 2024 Preclinical trials in Meningococcal group W-135 infections (Prevention) in China (Parenteral)